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Abstract
Objectives
The aim of this study was to investigate the expression of DAX-1 in a series of pediatric
rhabdomyosarcomas (RMS) with known translocation and compare it to Ap2β, known to be
selectively expressed in ARMS.
Design
We revised a series of 71 alveolar rhabdomyosarcomas (ARMS), enrolled in the Italian Pro-
tocols RMS 79 and 96, and 23 embryonal rhabdomyosarcomas (ERMS) as controls. Before
investigating Ap2β and DAX-1, ARMS were reviewed and reclassified as 48 ARMS and 23
non-ARMS.
Results
Translocation positive ARMS showed a characteristic Ap2β/DAX-1+ staining pattern in
78% of cases, while 76% of classic ERMS were negative for both. Ap2β alone was positive
in 3.9% of RMS lacking translocation, whereas DAX-1 alone was positive in 25.4%. Con-
versely, 9% and 6% of translocation positive ARMS were positive only for DAX-1 or Ap2β,
respectively. The 23 non-ARMS shared the same phenotype as ERMS but had a higher fre-
quency of DAX-1 expression.
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Conclusions
DAX-1 is less specific than Ap2β, however it is a sensitive marker for translocation positive
ARMS and can be helpful in their diagnosis if used in combination with Ap2β.
Introduction
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, accounting
for about 8% of all pediatric malignant tumors [1]. The current WHO classification recognizes
four main histological subtypes with distinctive clinico-pathological features: embryonal rhab-
domyosarcoma (ERMS), alveolar rhabdomyosarcoma (ARMS), spindle cells/sclerosing rhab-
domyosarcoma and pleomorphic rhabdomyosarcoma [2]. ERMS are more frequent in younger
patients, occur mostly in the genito-urinary region or orbit and lack specific recurrent genetic
alterations [3,4]. By contrast, ARMS typically occur in older children, are more frequent in the
extremities and behave more aggressively. About 80% of ARMS are characterized by recurrent
translocations, t(2;13)(q35;q14) or t(1;13)(p36;q14), resulting in 2 different fusion transcripts,
PAX3-FOXO1 and PAX7-FOXO1 respectively, encoding for proteins that act as aberrant tran-
scription factors [5,6]. Nevertheless, the histological definition of ARMS has been recently
under debate [3,7], suggesting that translocation negative ARMS may actually represent a
variant of ERMS, characterized by a less aggressive behaviour and better outcome that may
support the possibility of a less intensive treatment [7,8,9]. Genomic analysis of RMS plays an
important role in redefining their classification and identifying genes selectively expressed in
different RMS subtypes. The proteins encoded by some of these genes may be recognized by
commercially available antibodies and represent a useful diagnostic tool in clinical practice. In
particular, the TFAP2 gene (Ap2β) is highly expressed in translocation positive ARMS [10,11].
DAX-1 is an orphan nuclear receptor involved in gonadal development, sex determination
and steroidogenesis encoded by the NR0B1 gene. Beside playing an important role in the regu-
lation of stemness, under the control of the Nanog transcription factor in mouse embryonic
stem cells [12,13,14], it is also expressed in Ewing sarcoma/primitive neuroectodermal tumor
(PNET), in which it is up-regulated by the fusion transcript EWS-FLI1, promoting cell prolifer-
ation and inhibiting apoptosis [12,13,15]. DAX-1 positive expression has been reported only in
2 cases of translocation-positive ARMS [13] but it has never been systematically investigated in
RMS.
The aim of this study was to investigate the expression of DAX-1 and its potential role as a
diagnostic tool comparing it to the expression of Ap2β (encoded by TFAP2) in a series of RMS
with known translocation.
Materials and Methods
Ninety-four RMS enrolled in the Italian protocols RMS 79 and RMS 96 were retrieved from
the archives of the institutional and consultation files at the Pathology Department of the Uni-
versity of Padua. These included 71 cases diagnosed and treated as ARMS and 23 classic
ERMS, which were used as “controls”. HE stained sections, as well as desmin and myogenin
immunostains, were reviewed.
The 71 ARMS were reclassified, according to the current WHO classification, as: ARMS,
ERMS and spindle cell/sclerosing RMS. The group of RMS with mixed features of ERMS and
ARMS, previously classified as ARMS but probably representing a subgroup of ERMS, were
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classified as mixed RMS, and a new, provisional category of “epithelioid RMS”, recently
described by Jo et al., [16], was also introduced
Presence of anaplasia was also evaluated, according to the criteria used for Wilms’ tumor
[17,18].
In all cases, the diagnosis was then correlated with the results of reverse transcription
polymerase chain reaction (RT-PCR) analysis, for PAX3/PAX7-FOXO1 fusion genes. In 63
cases molecular investigations were performed at diagnosis on frozen tissue, in 8 on paraffin-
embedded tissue. RNA extraction was carried out from 4-μm slices. Samples from paraffin-
embedded tissue were dewaxed in two changes from d-limonene and washed three times in
ethanol (100%, 90% and 70%): rehydrated tissue was then incubated in lysis buffer mixture
containing proteinase-K (Absolutely RNA FFPE, Stratagene, Santa Clara, California). After
3–18 h of digestion at 55°C in lysis buffer, the RNA was extracted and then redissolved in
30 μL of RNase-free water elution (10 mM Tris-HCl, pH7.5). Samples from frozen tissue were
directly transferred in Eppendorf 1.5 Rnase free: tissue was then incubated in lysis buffer mix-
ture containing proteinase-K. After 3–18 hours of digestion at 55°C in lysis buffer, the RNA
was extracted and then redissolved in 30 μL of RNase-free water eluition (10 mM Tris-HCl,
pH7.5). 1 μg of RNA was retrotranscribed to cDNA with SuperScript III Reverse Transcriptase
(Invitrogen, MILANO). Quantitative RT-PCR for MyoD1, PAX3-FOX01 e PAX7-FOX01 was
performed on ABI Prism 7000 (Applied Biosystems, Foster City, California), with Taq-Man
technology. The ABL gene was used as positive control. Amplification and detection were per-
formed as follows: 40 cycles with 2 minutes at 50°C; 10 minutes at 95°C, 15 seconds at 95°C,
1 minute at 60°C (S1 Table).
In the cases in which the morphological features were those of a classic ARMS, the diagnosis
of ARMS was confirmed, even in the absence of the transcripts.
Immunohistochemical staining was performed on 3 μm formalin-fixed, paraffin-embedded
tissue sections using a fully automated system (Bond—maX, Leica, Newcastle Upon Tyne,
UK). Sections were dewaxed and rehydrated and incubated in retrieval buffer solution (Leica)
for antigen recovery. Specimens were then washed with phosphate-buffered saline (pH 7.0)
and incubated with the Bond Polymer Refine Detection Kit (Leica) according to the manufac-
turer’s protocols. Staining was visualized with 3,3’-diaminobenzidine, and the slides were coun-
terstained with Mayer’s hematoxylin. When not available or poorly preserved, immunostains
for desmin (DAKOCytomation, Clone D33) and myogenin/Myf4 (Novocastra, Clone LO26)
were newly performed. Immunostains for Ap2β (Santa Cruz Biotechnology, Rabbit Policlonal),
and DAX-1 (mouse monoclonal 2F4) [12,13,19] were performed using an automated immu-
nostainer. Ap2β and DAX-1 were considered positive when a strong nuclear staining was
found in the majority of cells (S2 Table).
Rhabdomyosarcoma cell lines (HTB-82, RD, RH-30, RH-41 and RUCH-2) were cultured
in DMEM (4.5 g/l glucose), supplemented with 10% FCS (Invitrogen) at 37°C in an atmo-
sphere containing 5% CO2. Whole cell extracts were obtained by homogenizing the cells in
hot Laemmli buffer and proteins were separated on SDS-PAGE and blotted on a polyvinyl
difluoride membrane (GE Healthcare, Indianapolis, IN). Membranes were blocked and incu-
bated with the primary antibodies, the anti-DAX-1 2F4 antibody [19] and the commercial anti
β-tubulin antibody (Sigma-Aldrich) for antigen detection, overnight at 4°C. Membranes were
incubated for 1 hour with horseradish peroxidase-conjugated antimouse or antirabbit antibody
(Amersham Biosciences). Detection was performed using an enhanced chemiluminescence
detection system from Roche on Kodak XK-1 films (Eastman Kodak Co., Rochester, NY)
[20,21].
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Chi-square test was performed in order to evaluate the correlation between DAX-1 pattern
of expression and histology. Fisher’s exact test was performed in order to evaluate the associa-
tion between the expression of DAX-1 and Ap2β.
Written consent for participation in the RMS 79 and RMS 96 studies had been requested
and obtained at the moment of each patient’s registration in the protocol. The study was
approved by the Ethics Committee of the University of Padua as part of the AIEOP (Italian
Association of Pediatric Hematology-Oncology) clinical trials.
Results
Clinical features
Patients’median age at diagnosis was 6.9 years (range 0–21). Tumor site was: limbs in 21, gen-
ito-urinary tract in 9, head-neck region in 12 (5 parameningeal, 7 non-parameningeal), and
other sites in 26. Tumor size at radiological investigations varied from 1 to 20 cm (mean diame-
ter 9.2). Stage of disease was available in 67 patients: 2 IRS I, 13 IRS II, 21 IRS III, and 31 IRS
IV. Follow-up varied from 4 to 20 years (median 7.3). Twenty-nine patients died of disease.
Pathological features
Seventy-one ARMS were re-classified as follow: 48 ARMS, 14 ERMS, 1 spindle cell/sclerosing
RMS, 4 mixed RMS, 4 epithelioid RMS [22].
Among the 48 ARMS, 40 showed classic morphology with cellular monotony and only
occasional rhabdomyoblastic differentiation. Four were solid and 4 showed histological fea-
tures difficult to be classified; in fact one had a very tiny biopsy and cytologic detail was poorly
preserved, another one displayed a solid pattern of growth of very primitive round cells without
evidence of rhabdomyoblastic differentiation, and scattered enlarged, very atypical nuclei and
in 2 cases cells were rather elongated. Forty-two tumors were translocation positive.
The group of tumors re-classified as ERMS included 5 cases of the so-called dense cellular
type ERMS [11], characterized by a very dense cellularity and primitive morphology, and 9
anaplastic ERMS, characterized by an unusual cytology, with enlarged nuclei resembling the
“nuclear unrest” of Wilms’ tumor and considered a precursor of anaplasia [4], together with
evidence of scattered, frankly anaplastic cells (Fig 1).
The spindle cell/sclerosing RMS showed an abundant sclerohyaline stroma with evidence of
nests and microalveoli mimicking classic alveoli of ARMS. There was no evidence of spindle
cell areas.
In all ERMS and spindle cells/sclerosing RMS, molecular analysis did not show any specific
translocation.
“Mixed” RMS were characterized by single or multiple nodules with features of classic
ARMS embedded in an embryonal neoplasm: in one case the alveolar clusters were predomi-
nant, in the other, alveolar areas were mixed with embryonal, spindle cell, sclerosing or epithe-
lioid areas.
Four epithelioid RMS, which are part of a recently published study by Zin et al., [22], were
characterized by large epithelioid cells arranged in solid sheets, resembling a rhabdoid tumor.
All of the 23 “control” cases with the original diagnosis of ERMS showed the classic
morphology.
Immunohistochemistry
Results of immunostains are summarized in Table 1. All tumors showed a positive staining for
desmin, ranging from strong and diffuse to focal. A strong positivity for Myf4 (Fig 2) in more
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than 50% of cells was detected in 84% of ARMS (37/43), 38.4% of tumors re-classified as
ERMS (5/14), and 50% of epithelioid and mixed RMS. A weak expression of Myf4 was found
in the single sclerosing RMS. Only 21% of classic ERMS (5/23) were diffusely positive for
Myf4.
DAX-1 was expressed in 31/38 ARMS (81.5%; 29 t+ and 2 t-), in 3/14 cases re-classified as
ERMS, in 50% of mixed RMS (2/4) and of epithelioid RMS (1/2), and in the sclerosing RMS.
Four out of 23 (17%) classic ERMS were DAX-1 positive. Interestingly, only 4 out of the 8 RMS
with non-classic morphology showed a strong and diffuse positive staining in more than 50%
of cells, in contrast to the remaining tumors, which showed weak nuclear staining (Fig 3).
All of the 14 new ERMS and 4 mixed RMS showed low or absent Ap2β expression. All 23
classic ERMS were negative for Ap2β, even in DAX-1-positive cases. Ap2β was expressed in
26/32 t+ ARMS and in 2/5 t- ARMS (Fig 4). The relationship between Ap2β and DAX-1 is
summarized in Fig 5.
DAX-1 expression in RMS cell lines
DAX-1 expression was present in four out of five cell lines examined (Fig 6); in two ARMS cell
lines (RH-30 and RH-41), in one ERMS cell line (HTB-82) and in one spindle cell/sclerosing
RMS cell line (RD). Another ERMS cell line was negative (RUCH-2).
Fig 1. (A) Hematoxylin and Eosin stained section from a tumor with initial diagnosis of ARMS, based
on the monotonousmorphology with round polygonal cells with hypercromatic nuclei (thin arrow),
embedded in a collagenized stroma (320x, scale bar 70 μm). (B) HE stained section from post-therapy
specimen shows a reduction of cellularity with scattered cells displaying anaplastic features (thick arrow) with
increased cell size (2-fold more than the adjacent cells) and nuclear hypercromasia. Atypical mitoses were
seen in other areas (100x, scale bar 210 μm).
doi:10.1371/journal.pone.0133019.g001
Table 1. Immunohistochemical pattern (according to histotype).
Reviewed Diagnosis (with translocation status) Number of cases #Myf4+/#cases (%) #Ap2β+/#cases (%) DAX-1+/#cases (%)
ARMS (t+) 42 32/37 (84) 26/32 (81) 29/33 (88)
ARMS (t-) 6 5/6 (83) 2/5 (40) 2/5 (40)
ERMS (t-) 14 5/14 (35) 0/14 (0) 3/14 (21)
RMSm (t-) 4 2/4 (50) 0/4 (0) 2/4 (75)
RMSep (t-) 4 2/4 (50) 0/4 (0) 1/2 (50)
RMSscl (t-) 1 0/1 (0) 0/1 (0) 1/1 (100)
ERMS (controls, t-) 23 (100) 5/23 (21) 0/23 (0) 4/23 (17)
ARMS: Alveolar Rhabdomyosarcoma; t+: translocation positive; t-: translocation negative; ERMS: Embryonal Rhabdomyosarcoma; RMSm: mixed
Rhabdomyosarcoma; RMSep: epithelioid Rhabdomyosarcoma; RMSscl: sclerosing/spindle cell Rhabdomyosarcoma.
doi:10.1371/journal.pone.0133019.t001
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Statistical analysis
DAX-1 immunohistochemical expression pattern in ARMS and case controls, constituted by
classic ERMS, was significantly different (p< 0.003). Fisher’s exact test showed a significant
association between the IHC expression of DAX-1 and Ap2β (p< 0.002).
Fig 2. (A) Immunostaining for Myf4 in histological sections of a t +ARMS, showing a positive nuclear
staining (brown cells) in more than 90% of cells. (B,C and D) Immunostaining for Myf4 in histological
sections of a ERMS, immunostained for Myf4, varying from scattered cells (< 20%) to more than 40% and
70% of cells respectively (160x, scale bar 120 μm).
doi:10.1371/journal.pone.0133019.g002
Fig 3. (A) Positive immunostaining for DAX-1 in histological section of a t+ ARMS. (B,C) Negative
immunostaining for DAX-1 in histological sections of two different ERMS. (D) Immunostaining for DAX-1 in
histological section of a ERMSwith the typically weak staining found in non-ARMS (80x, scale bars 240 μm).
doi:10.1371/journal.pone.0133019.g003
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Discussion
The histological overlap between some ARMS and ERMS related to their morphologic
heterogeneity [23,24,25,26,27,28,29,30] is one of the principal causes of the low diagnostic
agreement (80.9% and 63.0% for ARMS and ERMS respectively) even among expert patholo-
gists, as demonstrated by the IRSG-COG studies [17]. Recurrent translocations t(2;13)(q35,
q13.1) and t(1,13)(p36;q13.1), detected in 50% and 25% of alveolar RMS, respectively, make
the diagnosis of ARMS easier [16,31,32,33]. However it is not yet clear if rhabdomyosarcomas
with alveolar morphology lacking the translocation belong to the group of ARMS and should
be treated accordingly. Different reports on gene expression confirm the existence of a com-
mon molecular profile in t- ARMS and classic ERMS [34,35,36]. Moreover, a series of genes on
the RNA level have been found to have a high specificity in the discrimination between these
two subgroups, and might represent potential immunohistochemical markers. Myogenin is
highly expressed in ARMS, but it is not a completely reliable marker in the differential diagno-
sis between ARMS and ERMS, since its expression is highly variable in ERMS; conversely
AP2β (TFAP2) has been found to be selectively expressed in t+ ARMS and might represent a
helpful tool in the morphologic diagnosis. [10,11,37].
Fig 4. (A) Immunostaining for Ap2β in HE section of a t+ ARMS showing the typical alveolar pattern
and wreath-like cells (thin arrow) (320x, scale bar 60 μm). (C) Immunostaining for Ap2β in HE section of a
t+ ARMS, showing a diffuse nuclear staining in more than 90% of cells, in keeping with the presence of
translocation (160x, scale bar 120 μm). (B) Mixed RMS; HE staining show an alveolar pattern, with polygonal
cells lacking the monotony of an ARMS (320x scale bar 60 μm). (D) Negative Ap2β staining in HE section of
the same mixed RMS confirming the lack of translocation (80x, scale bar 240 μm).
doi:10.1371/journal.pone.0133019.g004
Fig 5. Pie charts showing the amounts of individual and co-expression of DAX-1 and Ap2β in ARMS t
+ and non-ARMS. (The arabic numbers indicate the number of positive tumors for each marker).
doi:10.1371/journal.pone.0133019.g005
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The present series well underlines the difficulty in the morphologic diagnosis of ARMS
and ERMS if we consider that only 48 out of 71 tumors initially diagnosed as ARMS were
confirmed. The major diagnostic difficulties were encountered in ERMS with dense cellularity
and primitive cytology, as already demonstrated [11], and in those RMS with a peculiar mor-
phology not fitting in the classic categories, such as epithelioid RMS and RMS with “nuclear
unrest”, i.e. with enlarged nuclei but not sufficient to define them as anaplastic. Sclerosing RMS
is frequently characterized by microalveolar areas that can be misinterpreted as classic alveoli
of ARMS. As reported in the recent WHO classification, mixed RMS, considered in the past as
ARMS, are probably ERMS, as confirmed by the absence of translocation in our cases [2].
Ap2β (TFAP2) immunostains are sensitive (81%) and highly specific (96%) in the detection
of t+ ARMS. The low sensitivity, as already reported by Wachtel et al., [10], may be related to
the inadequate antigenic preservation due, in some cases, to a prolonged or inadequate fixation.
Interestingly, 23 cases with an initial diagnosis of ARMS, and re-classified as ERMS, spindle
cell/sclerosing RMS and mixed RMS, were Ap2β negative. Among these cases myogenin
immunostains were strongly and diffusely positive in 9.
DAX-1 (NR0B1) is an orphan nuclear receptor playing a key role in the development
of adrenal gland [38,39]. Its expression in mouse embryonic stem cells is controlled by the
transcription factor Nanog [40]. The immunohistochemical expression of DAX-1 has been
reported to correlate with the presence of mRNA, evaluated with quantitative RT-PCR, con-
firming IHC as a valid evaluation tool [41]. Recent studies demonstrated that DAX-1 is abun-
dantly expressed by embryonic stem cells in an undifferentiated status and its level decreases
with differentiation. Knock-down of DAX-1 expression results in differentiation of embryonic
stem cells, suggesting a role of DAX-1 for the maintenance of undifferentiated state [42,43].
These features support a potential role of DAX-1 in tumorigenesis: in fact, it has been found to
be expressed in several adult malignancies, including endometrial carcinoma, ovarian carci-
noma, prostatic carcinoma and lung adenocarcinoma. Moreover, recent reports demonstrated
that DAX-1 can be regulated by EWS-FLI1 and is required for the transformed phenotype of
Ewing sarcoma cells [13,15,41], promoting cell proliferation. However, the role of DAX-1 in
Fig 6. Western Blot showing DAX-1 expression in 4 out of five cell lines. The asterisk indicates a non-
specific band present only in RMS cell lines. The histogram shows the relative amounts of DAX-1 expression
in each cell line. The densitometry was calculated (ImageJ software) as the ratio between the intensities of
the bands corresponding to DAX-1 for each cell line and the corresponding bands of β-tubulin multiplied by
100 and expressed in arbitrary units (AU).
doi:10.1371/journal.pone.0133019.g006
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deregulation of developmental pathways in pediatric cancer has not been further investigated.
DAX-1 expression in ARMS has been evaluated only in one study, which showed positivity in
2 cases of translocation-positive ARMS, but not in two cases of ERMS [13].
In the present series 29/33 t+ ARMS showed a strong and diffuse positive immunostaining
for DAX-1. DAX-1 immunostaining was more sensitive (88%), but less specific (41%) com-
pared to Ap2β. About 60% of RMS initially diagnosed as ARMS and reclassified as other sub-
types of RMS, except ERMS, showed a diffuse positivity, although only rarely comparable to
that of t+ ARMS; while, in control ERMS and in ERMS formerly diagnosed as ARMS, DAX-1
was present in 17% and 0% respectively. These data are confirmed by Western Blot analysis
that showed the presence of DAX-1 in 4/5 RMS cell lines (2/2 alveolar, 1/2 embryonal and 1/1
spindle cell/sclerosing). Moreover they also suggest that DAX-1 and alveolar morphology are
significantly associated and that this marker may be helpful in the distinction of classic ARMS
and ERMS. However, in the group of RMS with mixed features or in epithelioid and sclerosing
RMS, DAX-1 may be frequently expressed and should be studied in combination with Ap2β
and Myogenin. In fact, their combined use concurred to identify most of t+ ARMS (strong pos-
itivity of all three markers in 22, two in 3 and only one in 4 cases), while 9/17 RMS re-classified
as non-ARMS were negative for all markers. Remarkably, in Ewing sarcoma cells, the fusion
transcript EWS-FLI1 promotes directly DAX-1 expression, which regulates pathways involved
in cell growth and proliferation [14]: high DAX-1 expression in t+ ARMS may similarly corre-
late with genomic regulation mechanism triggered by fusion transcripts. However further stud-
ies are needed to investigate the relationship between DAX-1 and stem cell markers, in
particular Nanog 1, which is involved in the regulation of DAX-1 for the control of the stem
cell status.
In conclusion, as clearly stated in recent studies, the diagnosis of ARMS requires a molecular
confirmation, and Ap2β is a reliable immunohistochemical marker of t+ ARMS. Our study
demonstrates that DAX-1 is significantly associated with t+ ARMS and may be a useful adjunct
to Ap2β although less specific than Ap2β. As reported in other studies, the morphologic spec-
trum of translocation negative tumors, previously called ARMS on the basis of morphology
only, is wide and perhaps includes different subtypes characterized also by a higher expression
of DAX-1 compared to classic ERMS. However, the expression of DAX-1 in a subset of RMS
discloses new fascinating perspectives concerning its role in preventing cell differentiation and
promoting replication in analogy to the pathogenic mechanisms demonstrated in Ewing sar-
coma. New insights in the role of DAX-1 rhabdomyosarcoma tumorigenesis may lead to a
future development of novel targeted therapies [12].
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